Variable | Hazard ratio | 95Â % CI | p-value | |
---|---|---|---|---|
Age | Â | 0.99 | 0.97 - 1.03 | 0.836 |
Age (>60y) | Â | 0.51 | 0.24 - 1.11 | 0.089 |
Hepatic progression in FU (yes) | 0.8 | 0.37 - 1.73 | 0.566 | |
Systemic progression in FU (yes) | 1.57 | 0.78 - 3.17 | 0.209 | |
Under local control in FU (yes) | 0.31 | 0.14 - 0.68 | 0.004 | |
Her2 neu (pos) | Â | 1.22 | 0.59 - 2.53 | 0.588 |
Hormone receptor (pos) | 0.96 | 0.41 - 2.24 | 0.926 | |
Grading (1-3) | Â | 0.93 | 0.5 - 1.73 | 0.826 |
Other prior therapies for metastastes (yes) | 1.99 | 0.89 - 4.43 | 0.094 | |
Extrahepatic metastases (yes) | 2.86 | 1.39 - 5.87 | 0.004 | |
 | bones only | 3.01 | 1.49 - 6.08 | 0.002 |
First local treatment | Â | Â | Â | |
 | Brachytherapy (BT) or RFA | 0.28 | 0.13 - 0.59 | 0.001 |
 | Radioembolization (RE) | 3.31 | 1.57 - 6.98 | 0.002 |
 | Combination RE/BT or RE/RFA | 1.14 | 0.40 - 3.26 | 0.813 |
Best response hepatic (OR, RECIST) | 0.37 | 0.17 - 0.79 | 0.01 | |
Best response overall (OR, RECIST) | 0.15 | 0.07 - 0.34 | < 0.001 | |
Clinical and laboratory grade 3/4 toxicities (yes) | 1.83 | 0.78 - 4.31 | 0.168 | |
Number of liver metastases (≥ 6) | 2.08 | 1.01 - 4.31 | 0.048 | |
Maximum diameter of liver metastases (≥ 3.9 cm) | 3.43 | 1.57 - 7.52 | 0.002 | |
Liver volume (≥ 1376 mL) | 2.27 | 1.11 - 4.64 | 0.024 | |
Volume of liver metastases (≥ 27.9 mL) | 4.33 | 1.91 - 9.79 | < 0.001 | |
Tumor load (≥ 2 %) | 5.6 | 2.37 - 13.23 | < 0.001 | |
Lines of chemotherapy (≥ 3) | 3.17 | 1.55 - 6.49 | 0.002 | |
CA 15-3 (≥ 62.6U/mL) | 2.42 | 1.10 - 5.36 | 0.029 | |
CEA (≥ 6.2U/mL) | 3.36 | 1.58 - 7.15 | 0.002 | |
Time from first diagnosis to liver metastases (≥ 2y) | 0.79 | 0.40 - 1.56 | 0.492 | |
Concomitant or subsequent therapies for breast cancer metastases (yes) | 0.43 | 0.16 - 1.16 | 0.094 |